CN116744904A - 含有依匹斯汀或其盐和硫系抗氧化剂的经皮施予用医药组合物 - Google Patents

含有依匹斯汀或其盐和硫系抗氧化剂的经皮施予用医药组合物 Download PDF

Info

Publication number
CN116744904A
CN116744904A CN202180084690.1A CN202180084690A CN116744904A CN 116744904 A CN116744904 A CN 116744904A CN 202180084690 A CN202180084690 A CN 202180084690A CN 116744904 A CN116744904 A CN 116744904A
Authority
CN
China
Prior art keywords
pharmaceutical composition
salt
acid
epinastine
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180084690.1A
Other languages
English (en)
Chinese (zh)
Inventor
藤泽丰实
池田纮之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of CN116744904A publication Critical patent/CN116744904A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180084690.1A 2020-12-24 2021-12-23 含有依匹斯汀或其盐和硫系抗氧化剂的经皮施予用医药组合物 Pending CN116744904A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-215228 2020-12-24
JP2020215228 2020-12-24
PCT/JP2021/047943 WO2022138842A1 (ja) 2020-12-24 2021-12-23 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物

Publications (1)

Publication Number Publication Date
CN116744904A true CN116744904A (zh) 2023-09-12

Family

ID=82158746

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180084690.1A Pending CN116744904A (zh) 2020-12-24 2021-12-23 含有依匹斯汀或其盐和硫系抗氧化剂的经皮施予用医药组合物

Country Status (7)

Country Link
US (1) US20240058356A1 (https=)
EP (1) EP4268825A4 (https=)
JP (2) JP7171971B1 (https=)
KR (1) KR20230124625A (https=)
CN (1) CN116744904A (https=)
TW (1) TW202241448A (https=)
WO (1) WO2022138842A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022138842A1 (ja) * 2020-12-24 2022-06-30 参天製薬株式会社 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物
JP7638310B2 (ja) * 2022-02-28 2025-03-03 久光製薬株式会社 ジャー容器用のブテナフィン含有クリーム剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9611502A (pt) * 1995-11-14 1999-03-02 Boehringer Ingelheim Kg Uso de epinastina para o tratamento de dor
US20040247686A1 (en) * 2003-04-04 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
CN101217948A (zh) * 2005-07-08 2008-07-09 千寿制药株式会社 包含依匹那丁的透皮吸收眼科制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ242358A (en) * 1991-05-10 1994-03-25 Allergan Inc Use of thiol compounds to inhibit deposits on a contact lens
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
KR20050092429A (ko) 2003-01-22 2005-09-21 니찌방 가부시기가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법
JP5021155B2 (ja) * 2003-08-01 2012-09-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング エピナスチンと1種以上のさらなる抗−h1−ヒスタミン類との組合せを含む皮膚疾患治療用製薬組成物
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
ES2964555T3 (es) * 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
US20140271812A1 (en) * 2013-03-14 2014-09-18 Panacea Pharmaceuticals Treatment for chemotherapy-induced cognitive impairment
EP3302426A4 (en) * 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
WO2018203424A1 (ja) * 2017-05-01 2018-11-08 参天製薬株式会社 点眼剤
JP7458159B2 (ja) * 2018-09-28 2024-03-29 ロート製薬株式会社 眼科組成物
JP2019108320A (ja) * 2018-10-31 2019-07-04 参天製薬株式会社 ソフトコンタクトレンズの変質を抑制する眼科用組成物
JP6736752B2 (ja) * 2019-12-17 2020-08-05 参天製薬株式会社 エピナスチン含有点眼液
WO2022138842A1 (ja) * 2020-12-24 2022-06-30 参天製薬株式会社 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9611502A (pt) * 1995-11-14 1999-03-02 Boehringer Ingelheim Kg Uso de epinastina para o tratamento de dor
US20040247686A1 (en) * 2003-04-04 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
CN101217948A (zh) * 2005-07-08 2008-07-09 千寿制药株式会社 包含依匹那丁的透皮吸收眼科制剂

Also Published As

Publication number Publication date
JPWO2022138842A1 (https=) 2022-06-30
EP4268825A1 (en) 2023-11-01
US20240058356A1 (en) 2024-02-22
EP4268825A4 (en) 2024-12-11
TW202241448A (zh) 2022-11-01
JP7171971B1 (ja) 2022-11-15
EP4268825A9 (en) 2025-10-01
JP2023011818A (ja) 2023-01-24
KR20230124625A (ko) 2023-08-25
WO2022138842A1 (ja) 2022-06-30

Similar Documents

Publication Publication Date Title
US9289416B2 (en) Pharmaceutical dosage forms comprising 6′-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine
US10154959B1 (en) Ophthalmic composition containing a polyaphron dispersion
CN112135603B (zh) 包含奈必洛尔的药物组合物
RU2497516C2 (ru) Композиция для местного введения
JP6027549B2 (ja) タペンタドールを含む半固形の水性医薬組成物
US11779543B2 (en) Ocular drug delivery
JP7171971B1 (ja) エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物
US20250032520A1 (en) Oral cannabinoid compositions and methods for treating neurological diseases and disorders
JP7124248B1 (ja) エピナスチン又はその塩を含有する塗布投与用医薬組成物
JP6963651B2 (ja) エピナスチン又はその塩を含有する水性組成物
JP5897299B2 (ja) ローション剤
WO2025205960A1 (ja) エピナスチン又はその塩を含有する経皮投与用医薬組成物と抗アレルギー薬との組み合わせ
WO2007086582A1 (ja) 22-オキサ-1α,25-ジヒドロキシビタミンD3を含有する水中油型乳剤性ローション剤およびそれを用いた皮膚疾患の治療方法
CN116669705A (zh) 含有依匹斯汀或其盐的涂布施予用医药组合物
JP2025036319A (ja) クロルフェニラミンマレイン酸塩を含有する医薬組成物
HK40097614A (en) Pharmaceutical composition for topical administration containing epinastine or salt thereof
HK40091801A (zh) 含有依匹斯汀或其盐的涂布施予用医药组合物
JP7337791B2 (ja) デスロラタジン又はその塩を含有する医薬組成物
JP2024090835A (ja) 組織移行性を向上させるエピナスチン含有水性組成物
JP2024025725A (ja) 組成物
JP2024025726A (ja) 組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination